Healthcare · NYSE/NASDAQ: LLY
Eli Lilly and Company
Drug Manufacturers
Market Cap $850.00B
Verdict: Exceptional
Quality Scores
Multi-Bagger
94/100
Compounder Quality
93/100
Management Credibility
95/100
Governance
94/100
Cash Flow Quality
92/100
AI Summary
Eli Lilly has undergone a generational transformation, transitioning from a mid-sized pharma player to a global leader in metabolic health and oncology. The company's revenue trajectory shifted dramatically after 2019, driven by the explosive success of Mounjaro and Zepbound. Financial performance in the last two fiscal years (2024-2025) shows an unprecedented scaling of margins and net income, with PAT doubling year-over-year. Despite taking on debt to fund massive manufacturing expansions, the balance sheet remains robust relative to its market capitalization. This period represents one of…
Top Opportunities
- Leadership in GLP-1 market with Mounjaro and Zepbound
- Massive revenue acceleration (24.5B to 65.1B in 5 years)
- Tier-1 industry ROE exceeding 70%
Top Risks
- High valuation multiples compared to large-cap pharma peers
- Regulatory scrutiny on GLP-1 drug pricing
- Intense competition from Novo Nordisk (Ozempic/Wegovy)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.